Dan Promislow at ARDD2026: The Companion Dog as a Translational Model of Aging

Dan Promislow at ARDD2026: The Companion Dog as a Translational Model of Aging

Title history
  • Dan Promislow at ARDD2026: The Companion Dog as a Translational Model of Aging — observed on 20261026-2137 UTC (YouTube)

by Dan Promislow · View the channel on PSI

Life & Natural Systems Medicine & Health MFKHHuman growth and developmentMFKH3Maturation and ageing
🎙 Dan Promislow 👥 9K 📅 October 26, 2026 ⏱ 24 min 👁 12 📄 original study 🧭 2026-10-26
Available in: English (current) Français

Keywords

dog aging projectepigenetic clockmetabolomicsrapamycintranslational model

Summary

Dan Promislow presents the Dog Aging Project (DAP), a large-scale longitudinal study of companion dogs as a model for human aging. Over 55,000 dogs are enrolled, with a Precision Cohort of ~1,000 dogs providing annual biospecimens. The project integrates owner surveys, veterinary records, and multi-omic data, all made open to the academic community. Epigenetic clocks reveal that dogs with lower biological age live longer, and hypomethylated genes in aging dogs show expression increases in aging humans, suggesting shared mechanisms. Metabolomics identified 25 metabolites predicting mortality in dogs, enriched for kidney markers, with directions consistent across seven human studies, though within a much shorter 2.6-year follow-up. A GWAS linking a chromosome 25 SNP to kynurenic acid exemplifies cross-omic integration, and coat furnishing genes (RSPO2, FGF5) were found to also affect cystathionine levels. The TRIAD trial, a randomized double-blind placebo-controlled study of rapamycin in 580 dogs, is over 50% enrolled, with excellent safety so far; efficacy results are expected in ~4 years. The talk concludes with Q&A covering cohort expansion, sterilized-dog bias, potential links to sleep, and immune modulation.

177 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides high-value, original data from a unique longitudinal cohort, filling a gap between traditional model organisms and human studies. The argumentation is solid: each finding is clearly presented with methodological context, and cross-validation with human data strengthens translational implications. The speaker is transparent about limitations (e.g., owner demographics, sterilization bias) and careful not to overclaim, especially regarding the TRIAD trial where blinding is maintained. The reasoning flows logically from project overview to specific results, integrating genetics, epigenetics, and metabolomics convincingly.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high: the talk is based on a well-designed NIH-funded project with a large cohort, standardized biospecimen collection, and open data sharing. The upcoming Science paper (mentioned but not yet published) adds credibility. Sources cited include the Dog Aging Project’s own data, comparisons with human metabolomic studies (seven studies), and established biological pathways (e.g., tryptophan degradation). The title perfectly matches the content, and the description provided by the organizers aligns with the talk’s focus.

174 words

Title / Content Match

The title accurately reflects the content: a presentation on using companion dogs as a translational model for human aging, delivered at a major aging research conference.

Quality & Reliability

9/10

The talk is delivered by a leading researcher, presents rigorous findings from a large NIH-funded project with publicly available data, and includes multiple cross-validated observations (e.g., metabolite patterns matching human studies). The methodology and data handling are transparent, and the results are consistent with established scientific knowledge.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

Contribution & Novelties

The talk contributes original findings from a unique, large-scale companion dog cohort that bridges model organisms and human aging research. Notably, it presents longitudinal epigenetic clocks, metabolomic predictors of mortality with cross-species validation, and GWAS hits linking genetics to metabolite levels, all within a relatively short data collection period (2.6 years) compared to human studies. The TRIAD trial introduces the first real-world test of rapamycin in a large mammal. The open-data policy enhances reproducibility and collaboration.

Pour aller plus loin :

  • Epigenetic clock — A key concept used in the study to measure biological age from DNA methylation.
  • Metabolomics — The systematic study of metabolites, central to the mortality prediction findings.
  • Rapamycin — The drug tested in the TRIAD trial for its potential lifespan/healthspan effects.

125 words

Radar Profile

The radar profile shows uniformly high scores across all dimensions (quantity, quality, technical level, reliability), reflecting a dense, rigorous, and well-presented scientific talk with substantial original data and clear translational significance.

Reliability 9/10